Download Files:
Products Details
Product Description
– Ponesimod-d4 (ACT-128800-d4)is the deuterium labeledPonesimod(HY-10569)[1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[2][3][4].
Web ID
– HY-10569S
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C23H21D4ClN2O4S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
Molecular Weight
– 465.00
SMILES
– O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2C)/C(S/C1=CC3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC
Clinical Information
– No Development Reported
Research Area
– Others
Solubility
– 10 mM in DMSO
Target
– Isotope-Labeled Compounds;LPL Receptor
Pathway
– GPCR/G Protein;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
